Home / Reports

Reports

EU problematic patent settlements stabilize

The number of patent settlements between originator and generics companies concluded during 2013 has reduced compared to 2012. While the number of problematic or so-called ‘pay-for-delay’ deals have stabilized compared to 2012.

Biosimilars could save US$44.2 billion over 10 years

Introducing biosimilars of complex biologicals used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologicals in the US by US$44 billion over the next decade, according to an analysis carried out by the RAND Corporation.

UK uses less brand-name medicines per person

The UK uses fewer brand-name medicines per person than many other countries, but this means that the country tends to use older medicines rather than the latest ones, according to a new report.

Generics makers challenging more patents

In recent years generics makers are becoming bolder and challenging more patents on originator drugs. In fact, litigation regarding patents on pharmaceuticals is on the rise, particularly when it comes to newer drugs.

Growth in Netherlands pharma market held back by generics policies

The pharmaceutical market in The Netherlands will rise slowly from approximately US$6.7 billion in 2014 to US$7.2 billion by 2020. Growth is being restricted by the government’s focus on generics as a cost-containment tool, according to research and consulting firm GlobalData.

Biosimilars use in Europe varies widely

Use of biosimilars in Europe varies widely between countries and therapy areas, according to a report published by IMS Health in October 2014.

Development of biosimilars for rheumatoid arthritis

Biosimilars development is a hive of activity, with development of biosimilars for the treatment of rheumatoid arthritis being one of the busiest areas in the biosimilars field, see Table 1 [1].

Patients satisfied with generics

A report by health information resource, Iodine, has found that patients have a similar level of satisfaction with generics compared to brand-name drugs.

Generics save US 1.5 trillion over last 10 years

Generics have saved consumers and the US healthcare system US$239 billion in 2013 and have saved the US nearly US$1.5 trillion between 2004 and 2013, according to a report by the Generic Pharmaceutical Association (GPhA) [1].

Generics and biosimilars contribute to European drug savings

As governments around the world try to rein in healthcare expenses, generics and biosimilars can play a major role in reducing this budgetary burden [1].